Tags |
|
|
Links |
|
|
Advice You - There Is Nothing Wrong With Winning On Price!
So many business leaders and MBA professors say that cutting prices actuall
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
y hurts profits and it hurts the industry and no one wins. This may be well
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
documented in industries where price competition was not applied correctly
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
or one company started dumping into the market in order to increase market
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
share, but if a company is truly on the ball and has their systems, supply
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
hains, manufacturing processes and management under control and they are op
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
erating as efficiently as possible, then their business model should allow
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
them to win a price war.
In fact in reality; There is nothing wrong with w
In fact in reality; There is nothing wrong with w
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
nning on Price! And there is nothing wrong with winning. Artificial market
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
or industry price boosting actually can be a bad thing, because it makes co
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
panies weak and fat, instead of lean and trim and ready to complete the mar
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
athon at a record breaking pace. I would like to state for the record that
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
if you cannot beat your competition on price if they start a price war, the
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
you are not as efficient as you should be.
In that case you are too fat a
In that case you are too fat a
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
nd no longer have the agility of a start up in the market place and have sl
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
pped into a micro-managed stodgy, bureaucracy and well, in that case, my De
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ar Sir, I am not impressed, because I think you are weak and have lost your
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
competitive edge and therefore my friend you better check six, because the
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
whole nine yards are loaded and we plan to win, using any and ALL methods p
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
ossible including perhaps cutting price to do so. Consider all this in 2006
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/2409/adviceyou-There-Is-Nothing-Wrong-With-Winning-On-Price.html">There Is Nothing Wrong With Winning On Price!</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/2409/adviceyou-There-Is-Nothing-Wrong-With-Winning-On-Price.html]There Is Nothing Wrong With Winning On Price![/url]
Related Articles:
Help! My Boomers Are Retiring!
Bookmark it:
|